Early Intervention and Prevention of Non-Alcoholic Fatty Liver Disease in Adolescents
Public ClinicalTrials.gov record NCT02116192. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This research study intends to learn about whether early intervention can help to prevent non-alcoholic fatty liver disease (NAFLD) in adolescents. Potentially eligible adolescents who are seen at the University of Wisconsin (UW) Pediatric Fitness Clinic will be asked to join the study. Patients who agree to participate in the study will be randomized into either the intervention group or the control group. The intervention group will follow a low-fructose diet. In addition, participants will be asked to return to the clinic for 4 follow-up visits during a 6-month interval.
Study identification
- NCT ID
- NCT02116192
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Not applicable
- Enrollment
- 28 participants
Conditions and interventions
Conditions
Interventions
- Experimental: Low-fructose, reduced carbohydrate diet Behavioral
- General Healthy Diet Behavioral
Behavioral
Eligibility (public fields only)
- Age range
- 11 Years to 17 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 31, 2014
- Primary completion
- Jun 30, 2016
- Completion
- Sep 30, 2017
- Last update posted
- Oct 10, 2018
2014 – 2017
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Park Clinic | Madison | Wisconsin | 53711 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Non-alcoholic Fatty Liver Disease trials
Other public records listing Non-alcoholic Fatty Liver Disease. Sorted by last update posted; newest first. Not a recommendation.
- NCT06005012: Semaglutide Treatment in the Real-world for Fibrosis Due to NAFLD in Obesity and T2DM Active, not recruiting
- NCT07403604: Effect of Insulin Lowering on Lipogenesis Recruiting
- NCT05583344: Phase 2b Study of GSK4532990 in Adults With NASH Active, not recruiting
- NCT04951219: A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE) Active, not recruiting
- NCT03884075: Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES) Recruiting
- NCT07221227: A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02116192, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 10, 2018 · Synced Sep 4, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02116192 live on ClinicalTrials.gov.